Teva Pharmaceutical Industries Limited (TEVA) Holdings Boosted by Lafayette Investments Inc.

Lafayette Investments Inc. raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 44.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,401 shares of the company’s stock after buying an additional 4,400 shares during the quarter. Lafayette Investments Inc.’s holdings in Teva Pharmaceutical Industries were worth $253,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Capital Research Global Investors grew its holdings in shares of Teva Pharmaceutical Industries by 13.8% during the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 11.1% during the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after purchasing an additional 6,685,844 shares during the last quarter. FMR LLC grew its holdings in shares of Teva Pharmaceutical Industries by 16.7% during the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares during the last quarter. Northern Cross LLC grew its holdings in shares of Teva Pharmaceutical Industries by 14.0% during the 2nd quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after purchasing an additional 2,184,172 shares during the last quarter. Finally, Nordea Investment Management AB grew its holdings in shares of Teva Pharmaceutical Industries by 2.5% during the 2nd quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after purchasing an additional 311,894 shares during the last quarter. 52.05% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts recently issued reports on the stock. Credit Suisse Group reaffirmed an “underperform” rating and set a $8.00 price target (down from $14.00) on shares of Teva Pharmaceutical Industries in a report on Monday, November 6th. Royal Bank Of Canada decreased their price target on shares of Teva Pharmaceutical Industries from $21.00 to $15.00 and set an “underperform” rating on the stock in a report on Monday, September 18th. Wells Fargo & Company reiterated a “market perform” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, October 5th. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Sunday, November 12th. Finally, BTIG Research set a $16.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Tuesday, November 28th. Seven analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $21.65.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down $0.21 during midday trading on Tuesday, hitting $15.05. 12,780,500 shares of the stock were exchanged, compared to its average volume of 15,670,381. The firm has a market cap of $15,500.00, a P/E ratio of 3.52 and a beta of 0.55. Teva Pharmaceutical Industries Limited has a 1 year low of $10.85 and a 1 year high of $38.31. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a $0.085 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.26%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is currently -12.27%.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/12/05/teva-pharmaceutical-industries-limited-teva-holdings-boosted-by-lafayette-investments-inc.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply